Be the first person to write a business review for Charles River Laboratories International, Inc.

Chelsea Therapeutics International, Ltd. was founded in 2002 and is headquartered in Charlotte, North Carolina. Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It offers droxidopa, an orally active synthetic precursor of norepinephrine, which is in two double-blind pivotal Phase III trials for the treatment of symptomatic neurogenic orthostatic hypotension, freezing gait in Parkinson's disease, and intradialytic hypotension; for the treatment of intradialytic hypotension for which it has completed a double-blind placebo controlled Phase II study; and for the treatment of fibromyalgia that is in a Phase II trial.Chelsea Therapeutics company also offers a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, such as a portfolio of metabolically inert antifolate molecules, including CH-1504 for the treatment of rheumatoid arthritis that is in a Phase II head-to-head clinical trial; and CH-4051, which is in the Phase I study designed to determine the maximum tolerated dose based on results of single-ascending and multiple-ascending dose evaluations. In addition, it develops antifolate program, a second platform consisting of a portfolio of dihydroorotate dehydrogenase(DHODH), inhibiting compounds known as the I-3D portfolio, a group of orally active compounds that inhibit the enzyme DHODH for the treatment of immune-mediated inflammatory disorders, including transplant rejection, autoimmune diseases, psoriasis, and systemic lupus erythematosus.

ChemGenex Pharmaceuticals is looking for treatments that are tailor-made for different patients. The company is researching targeted cancer therapies, finding genetic differences that affect how well patients respond to certain drugs and tailoring therapies accordingly. Its lead candidate is omacetaxine mepesuccinate (formerly called Ceflatonin); the drug is undergoing clinical testing as a treatment for chronic myeloid leukemia in patients who have a genetic mutation that makes them resistant to Novartis' Gleevec. Also in clinical development is Quinamed, a potential tumor fighter. The company has several other preclinical oncology programs as well.

ChemOvation offers contract drug discovery research and design services to pharmaceutical and biotechnology companies. ChemOvation has expertise in organic and medicinal chemistry, and drug discovery. ChemOvation also provides protein binding and compound solubility measurements for clients' metabolism research. ChemOvation's team of contractors is built around a core of organic chemists and technicians. Formed in 1999, the company merged with KuDOS Pharmaceuticals in 2000. ChemOvation dissolved those bonds in 2005 having spun off from KuDOS and is independent once again.

Chesapeake PERL was founded in 2000. Chesapeake PERL calls a "mini bioreactor" to produce proteins. Using its PERLXpress technology platform, the company mass produces antibodies, enzymes, viral antigens, and other proteins in whole insect larvae. It sells its custom protein development services, as well as some research reagents, to biotech concerns, including drug and diagnostics companies, biotech instrument makers, agricultural companies, and makers of industrial enzymes. It has also received federal grants from the NIH, the US Army, and the US Department of Energy.

When new drugs are tested, someone has to go first and Chiltern (Early Phase) Ltd. (formerly Drug Development Solutions) will help find that person. A contract research organization (CRO), the company specializes in bridging the gap between preclinical studies and the early stages of clinical trials in humans for drug candidates. Its clients include large multinational companies as well as small biotech startups. The company's facilities are based inside a major hospital with access to emergency medical care if needed. The company was spun off from the University of Dundee in 1982 and then acquired by CRO giant Chiltern International in 2008.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.